While investment opportunities are expanding, fundraising cycles are becoming longer, as investors demand more validation before committing capital. With VCs becoming more risk-averse, start-ups will need to work harder to secure funding, even for the most promising innovations.

Through our basecamp and tailored support program, we continue to support biotech start-ups navigating these challenges, providing the resources and network they need to thrive in an evolving investment landscape.